This page is updated frequently with new Proteins-related patent applications.
| Multiplex mrm assay for evaluation of cancer|
The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (er), progesterone receptor (pr), and/or antigen ki67 (ki67) proteins that are particularly advantageous for quantifying the er, pr, and/or ki67 proteins directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring/multiple reaction monitoring (srm/mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
Expression Pathology, Inc.
| Genetically encoded fluorescent sensors for detecting ligand bias and intracellular signaling through camp pathways|
Described herein are novel fluorescent sensors for cyclic adenosine monophosphate (camp) that are based on single fluorescent proteins. These sensors use less visible spectrum than fret-based sensors, produce robust changes in fluorescence, and can be combined with one another, or with other sensors, in a multiplex assay on standard fluorescent plate readers or live cell imaging systems..
Montana Molecular Llc
| Zwitterionic reagents|
Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility.
Siemens Healthcare Diagnostics Inc.
| Solid medium for the storage of biological material|
This invention relates to flat solid media for the storage of samples of biological materials and methods of analysing biomolecules contained within the samples following storage. In particular, the invention relates to the storage and further analysis of biomolecules present in the biological materials, such as proteins, enzymes and nucleic acids.
Ge Healthcare Uk Limited
| Expression system for producing protein having a n-terminal pyroglutamate residue|
Disclosed herein is an expression system and uses thereof. The expression system comprises two vectors that express two fusion proteins and a glutaminyl cyclase (qc) with e45q mutation, so as to autonomously produce a target protein having a n-terminal pyroglutamate (pglu) residue in a host cell.
| Transgenic plants with enhanced agronomic traits|
This invention provides transgenic plant cells with recombinant dna for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency, enhanced cold tolerance, increased yield, enhanced nitrogen use efficiency, enhanced seed protein and enhanced seed oil.
Monsanto Technology Llc
| Compositions and methods for differential regulation of fatty acid unsaturation in membrane lipids and seed oil|
Aspects of the invention provide methods for differential regulation of fatty acid unsaturation in seed oil and membrane lipids of plants based on modulation of a previously unknown biosynthetic pathway involving a novel phosphatidylcholine:diacylglycerol cholinephosphotransferase (pdct) that regulates phosphatidylcholine biosynthesis in developing oil seed plants. Specific aspects relate to inventive pdct polypeptides including, for example, variants, deletions, muteins, fusion proteins, and orthologs thereof (collectively pdct proteins), to nucleic acids encoding same, to plants comprising such pdct sequences or proteins or devoid or depleted of such pdct proteins or sequences, and to methods for generating plants having altered or no pdct expression and/or activity, including but not limited to methods comprising mutagenesis, recombinant dna, transgenics, etc..
Washington State University
| Chemically modified short interfering nucleic acid molecules that mediate rna interference|
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions.
Sirna Therapeutics, Inc.
| Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same|
Provided are variant adenosine deaminase 2 (ada2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ada2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker..
| Manganese superoxide dismutase variants and uses thereof|
The present invention concerns variant proteins of manganese superoxide dismutase and uses thereof. In particular, the proteins of the invention have medical and diagnosis applications.
Soluble hiv-1 envelope glycoprotein trimers
The present application relates to novel hiv-1 envelope glycoproteins which may be utilized as an hiv-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
The Scripps Research Institute
The invention provides to ntrk (“neurotrophic tyrosine receptor kinase) gene fusions, ntrk. Fusion proteins, and fragments of those genes and polypeptides.
Blueprint Medicines Corporation
Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof
An antibody or antigen-binding fragment thereof which specifically binds the α3 domain of a hla-g protein, in particular binds the β2-microglobulin free hla-g protein exhibiting an α3 domain. The nucleic acid molecules encoding a human hla-g α3 domain polypeptide, which is selected from a group of specific sequences, and vectors for the cloning and/or expression of such nucleic acid molecules, recombined cells or cell lines and compositions for use in a host in need thereof to interfere with and neutralize the immune down-regulation due to hla-g proteins, and/or improving or treating conditions showing hla-g+ lesions, and/or improving or treating a neoplasic condition or disease.
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity..
Roche Glycart Ag
Antibody drug conjugates (adc) that bind to flt3 proteins
Antibody drug conjugates (adc's) that bind to flt3 protein and variants thereof are described herein. Flt3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in table i.
Targeting tissue factor to activated platelets
The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament.
Novo Nordisk A/s
Il-13 binding proteins and uses thereof
Novel anti-il-13 antigen-binding proteins such as antibodies and antigen-binding fragments thereof are provided. Methods of using the proteins to reduce il-13 activity and to treat il-13-associated diseases and conditions are further provided..
Tnf-alpha binding proteins
Tnf-α binding proteins, including chimeric, cdr-grafted, and humanized antibodies that bind tnf-α are provided. Binding proteins have high affinity for tnf-α and neutralize tnf-α activity.
Production of recombinant proteins with simple glycoforms
The present invention provides cell lines deficient in mannosyl (alpha-1,3-)-glycoprotein beta-1,2-n-acetylglucosaminyltransferase i (mgat1). Also provided are methods for producing the mga1 deficient cell lines and methods for using the mgat1 deficient cell lines for the production of recombinant proteins having simple glycoforms..
Sigma-aldrich Co. Llc
Order a batch download of a huge number of patent PDFs.
Bulk PDF DownloadsThis is a premium service.
Cd27 single chain molecules
The present invention refers to single-chain fusion proteins comprising three soluble tnf superfamily (tnfsf) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications..
Purification of proteins
This application relates to methods for purification of proteins such as antibodies using a hydrophilic polymer (e.g., peg), a fatty acid (e.g., caprylic acid), and/or another agent (e.g., calcium chloride).. .
Universitat Fur Bodenkultur Wein
Isolation and purification of dvd-igs
Chromatographic methods for isolating and purifying dvd-lgs™ from a sample, wherein the purified dvd-lgs™ have reduced host cell proteins, aggregates, and viruses compared to the sample.. .
Compounds and methods for the enhanced degradation of targeted proteins
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a vhl ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein.
Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases
Furthermore, the present invention relates to the use of the dihydropyrido[3,4-b]pyrazinones according to the invention in viral infections, in neurodegenerative disorders, in inflammation disorders, in atherosclerotic disorders and in male fertility control.. .
Photocleavable chemical inducers of dimerization (cid) and methods of use
The instant invention provides photolysable compounds, and their use in reversible chemical induced dimerization and light-induced regulation of proteins.. .
President And Fellows Of Harvard College
Triorthogonal reagents for dual protein conjugation
The present invention relates to triorthogonal reagents useful for site-specifically modifying a protein with two orthogonal groups that can be subsequently functionalized in a single one-pot procedure. This approach relies on the selective tagging of proteins containing an appended farnesyltransferase or geranylgeranyltransferase i substrate sequence.
Regents Of The University Of Minnesota
A composition including lactoferrin and immunoglobulin, wherein the composition does not substantially include one or more of the following proteins: lactoperoxidase, lactoglobulin, albumin.. .
Subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand rna virus as carriers of heterologous polypeptides
The present invention relates to a subunit vaccine platform based on multimeric ribonucleoproteins (rnps) comprising nucleoproteins of a non- segmented negative-strand ribonucleic acid (rna) virus as carriers of heterologous polypeptides. The present invention also relates to multimeric rnps resulting from the assembly of at least 200 fusion proteins with a cellular rna, or to recombinant yeasts or yeast lysates expressing these multimeric rnps.
Universite Paris Diderot - Paris 7
Tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi) - anchors for treatment of cancer and skin lesions
The present invention relates to fusion constructs of glycosylphosphatidylinositol (gpi)-anchored tissue inhibitors of metalloproteinases (timps) and their use for the treatment of cancer and in regenerative medicine. By this approach, the gpi-anchored timp proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to fas-induced apoptosis.
Treating cancer stem cells using targeted cargo proteins
The disclosure provides targeted cargo proteins that are useful for targeting cancer stem cells, and methods of their use in treating cancer.. .
Medicenna Therapeutics Inc.
Described herein is the discovery that hgfs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients hgfs, or proteins or compounds functionally equivalent thereto.
Anges Mg, Inc.
The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin b12 and, optionally, agents that impact heme protein metabolism..
Fred Hutchinson Cancer Research Center
Intra-amniotic administration of proteins for the treatment of ectodermal dysplasias
The invention relates to methods for the intra-amniotic administration of eda agonists, in particular edi200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, xlhed..
Method for analyzing protein-protein interaction on single-molecule level in cell environment, and measuring density of protein activated in cytosol
A method of analyzing protein-protein interactions at a single molecular level is disclosed. The method of analyzing the interactions between first proteins and second proteins at the single molecular level includes: preparing at least two substrates, in which first protein-binding molecules that are biomolecules to be bound to the first proteins are attached to each of the substrates; inducing binding between the first proteins and the first protein-binding molecules on the first substrate and the second substrate, respectively, by supplying the first proteins included in the control group-cell to the first substrate among the two substrates and supplying the first proteins included in the experimental group-cell to the second substrate among the two substrates; supplying cell lysates of cells including the marker-tagged second proteins to the first substrate and the second substrate, respectively, when the first proteins and the first protein-binding molecules are bound to the first substrate and the second substrate, respectively; and comparing and analyzing the interactions between the first proteins and the second proteins on the first substrate and the second substrate in the supply of the cell lysates to the first substrate and the second substrate, respectively.
Korea Advanced Institute Of Science And Technology
Method and device for protein preparation
The present invention provides a method of preparing a sample comprising one or more proteins of interest, the method comprising: providing a sample comprising a population of proteins of interest solubilised with a surfactant in a medium; exposing said sample to a mild precipitant to cause precipitation of said proteins; during or after the precipitation step, bringing said sample into contact with a matrix adapted to capture said precipitated proteins and prevent excessive aggregation of precipitated protein particles; and washing the matrix with captured precipitated proteins to remove the surfactant. A sample preparation device to carry out the same is also provided..
University Of Leeds
System and non-reductive beta-elimination isolation and analysis
A laboratory method and system used to isolate and analyze o-linked oligosaccharides from glycoproteins that uses non-reductive β-elimination (nbre). The method including the step of providing a predetermined amount of solution and then passing it through an ion exchange resin.
Digital assay for quantifying and concentrating analytes
Provided herein are methods, compositions, and devices for the identification and quantification of analytes, such as nucleic acids, proteins, cells or other biological samples. The methods, compositions, and devices are suited for accurate, portable analysis of small amounts of analyte..
University Of Chicago
Cells having disrupted expression of proteins involved in adme and toxicology processes
The present invention provides cells comprising disrupted expression of at least one membrane transporter, drug metabolizing enzyme, xenobiotic sensor, or cellular stress response pathway protein. Also provided are methods for assessing the effect of an agent in the cells disclosed herein relative to comparable control cells..
Sigma-aldrich Co. Llc
Frequency domain discrimination of tissue proteins
Devices and methods for performing frequency domain (fd) fluorescence lifetime spectroscopy are provided. The devices include a modulated light source, a focusing optical fiber, a detecting optical fiber, and a detector.
The Regents Of The University Of Michigan
Order a batch download of a huge number of patent PDFs.
Bulk PDF DownloadsThis is a premium service.
Electroblot transfer buffer
A semi-dry, one step electroblot transfer buffer composition for rapid transfer of proteins or polypeptides from polyacrylamide gel to a suitable membrane such as nitrocellulose or polyvinylidene difluoride (pvdf). The composition contains components that minimized electrical resistance and enabled high efficiency rapid semi-dry transfer using conventional readily available filter paper, i.e., cotton cellulose fiber..
Pierce Biotechnology, Inc.
Sample preparation analysis of platelet proteins
The present invention provides a novel method of in vitro sample preparation for the analysis of proteins. In a first aspect, the present invention is a method comprising the separation and individual treatment of blood platelets and platelet-poor plasma obtained from a platelet-rich plasma sample.
Randox Laboratories Ltd
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection..
Nucleic acid ligand diagnostic biochip
A nucleic acid ligand “biochip” is disclosed, consisting of a solid support to which one or more specific nucleic acid ligands is attached in a spatially defined manner. Each nucleic acid ligand binds specifically and avidly to a particular target molecule contained within a test mixture, such as a bodily fluid.
Methods for producing a paired tag from a nucleic acid sequence and methods of use thereof
Methods for producing a paired tag from a nucleic acid sequence are provided in which the paired tag comprises the 5′ end tag and 3′ end tag of the nucleic acid sequence. In one embodiment, the nucleic acid sequence comprises two restriction endonuclease recognition sites specific for a restriction endonuclease that cleaves the nucleic acid sequence distally to the restriction endonuclease recognition sites.
Applied Biosystems Llc
Engineered cleavage half-domains
Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence..
Sangamo Biosciences, Inc.
Engineering neural stem cells using homologous recombination
Described herein are recombinant polynucleotide-binding polypeptides, recombinant fusion proteins made with the described polynucleotide-binding polypeptides, methods of using the described recombinant polynucleotide-binding polypeptides and recombinant fusion proteins to modify genomic dna of cells and, in some embodiments, create recombinant cells. Methods are also provided herein for genetically modifying a neuronal stem cell.
The United States Of America, As Represented By The Secretary, Department Of Health & Human
Transgenic plants with enhanced agronomic traits
This invention provides transgenic plant cells with recombinant dna for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency; enhanced cold tolerance, increased yield, enhanced-nitrogen use efficiency, enhanced seed protein and enhanced seed oil.
Monsanto Company, Llc
Recombinant glycoproteins and uses thereof
Provided herein are recombinant glycoproteins (e.g., recombinant human α-galactosidase-a proteins) with an altered (e.g., improved) glycosylation profile, and pharmaceutical compositions and kits including one or more of these proteins. Also provided are methods of generating a mammalian cell useful for recombinant expression of a glycoprotein (e.g., recombinant human α-galactosidase-a), methods of producing recombinant glycoproteins, and methods of treatment that include administering to a subject at least one of the recombinant glycoproteins (e.g., recombinant human α-galactosidase-a protein)..
Virus purification and formulation process
Disclosed herein is provided a virus purification and formulation process for purifying a flavivirus represented by one of a a yellow fever virus, japanese encephalitis virus, dengue virus, and west nile virus. The highly purified flavivirus virus product is characterized as having a low level of sucrose without significant virus loss such as that which is typically encountered by prior art virus purification processes.
Ge Healthcare Bio-sciences Corp.
Tslp binding proteins
The present disclosure relates to tslp binding proteins, such as anti-tslp single variable domains, polynucleotides encoding such tslp binding proteins, pharmaceutical compositions and kits comprising said tslp binding proteins and methods of manufacture. The present invention also concerns the use of such tslp binding proteins in the treatment of diseases associated tslp signaling, such as asthma..
Glaxosmithkline Intellectual Property Development Limited
Anti-ngf antibodies and their use
The present disclosure encompasses ngf binding proteins, specifically to antibodies that are chimeric, cdr grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting ngf and for inhibiting ngf activity, e.g., in a mammal subject suffering from a disorder in which ngf activity is detrimental..
Zoetis Belgium S.a.
Broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibody
The invention provides a method for obtaining a broadly neutralizing antibody (bnab), including screening memory b cell cultures from a donor pbmc sample for neutralization activity against a plurality of hiv-1 species, cloning a memory b cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory b cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the env proteins in native or monomeric form, as well as to inhibit infection of hiv-1 species from a plurality of clades.
International Aids Vaccine Initiative
Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides
The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (rbd) of the spike (s) glycoprotein of the middle east respiratory syndrome coronavirus (mers-cov). The polypeptides and fusion proteins can be used to treat and prevent mers-cov infection in mammals..
The University Of Hong Kong
Production of human pulmonary surfactant protein b in plants
The invention is directed to a method of producing pulmonary surfactant protein-b (sp-b) isoforms fragments and analogues thereof in a plant cell, and to expression cassettes for expression of the sp-b proteins in plants. The expression cassettes may include various elements for improved expression, stability of the expressed protein or efficient purification of the expressed protein, including signal sequences, protease cleavage sites for release of the target protein, trafficking peptides for trafficking of the expressed protein to various plant compartments, and/or various tags..
Azargen Biotechnologies (pty) Ltd
Variant activin receptor
The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
Consumable cryopreserved cells transiently overexpressing gene(s) encoding drug transporter protein(s) and/or drug metabolizing enzyme(s)
The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes..
Water soluble membrane proteins and methods for the preparation and use thereof
The present invention is directed to water-soluble membrane proteins, methods for the preparation thereof and methods of use thereof.. .
Massachusetts Institute Of Technology
Peptide inhibitors of tead/yap-taz interaction
The invention relates to an isolated peptide inhibitor of the interaction between the tead and yap or taz proteins and a derived chimeric peptide linked to a cell-penetrating peptide. These peptides which have a cytotoxic activity are useful, in particular for the treatment of hyperproliferative disorders such as cancer..
Fluorescent and colored proteins and methods for using them
The field of this invention relates to methods for combining genetic elements such that the activity of one of the elements provides a means for identifying, enriching, selecting for, or enhancing the activity of a second element. The invention also includes specific elements and combinations of elements..
Dna Twopointo, Inc.
Order a batch download of a huge number of patent PDFs.
Bulk PDF DownloadsThis is a premium service.
Nucleic acids and proteins from streptococcus groups a and b
The invention provides proteins from group b streptococcus (streptococcus agalactiae) and group a streptococcus (streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.
J. Craig Venter Institute, Inc.
Composition for preventing mycoplasma spp. infection
The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against mycoplasma spp. The present invention also provides a subunit vaccine made therefrom.
Agricultural Technology Research Institute
Novel adenovirus isolated from titi monkeys
Provided is a titi monkey adenovirus (tmadv) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-tmadv antibodies, vaccines, compositions, methods of detecting tmadv, methods for assaying for anti-tmadv compounds, and methods for treating or preventing a tmadv infection..
The Regents Of The University Of California
Therapeutic compounds and methods
Regulator of g protein signaling (rgs) proteins modulate the complex signaling pathways elicited by g protein coupled receptor activation. Recent studies have implicated rgs proteins in the development and progression of multiple cancers.
University Of Iowa Research Foundation
Method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair
A medical composition is disclosed, which is injectable and which comprises a mixture of native components, which are obtainable by culturing one or more cell samples from a human or animal during normal conditions, said native components being included in the group consisting of growth factors, extracellular matrix proteins, and other substances produced by said cell samples during normal conditions, and a pharmaceutically acceptable carrier, as well as a method for producing the native components, a method for producing the medical composition, a method for treating a subject in need of tissue repair by injection of the medical composition, and use of said mixture of native components for the production of said medical composition for tissue repair via injection. A medical composition is disclosed, which is injectable and which comprises a mixture of native components, which are obtainable by culturing one or more cell samples from a human or animal during normal conditions, said native components being included in the group consisting of growth factors, extracellular matrix proteins, and other substances produced by said cell samples during normal conditions, and a pharmaceutically acceptable carrier, as well as a method for producing the native components, a method for producing the medical composition, a method for treating a subject in need of tissue repair by injection of the medical composition, and use of said mixture of native components for the production of said medical composition for tissue repair via injection..
Antibody drug conjugates (adc) that bind to 191p4d12 proteins
Antibody drug conjugates (adc's) that bind to 191p4d12 protein and variants thereof are described herein. 191p4d12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in table i.
Seattle Genetics, Inc.
Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming
Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transduction reagent is non-covalently bound to the reprogramming protein and wherein the protein transduction reagent comprises a cation reagent and a lipid. According to aspects, such methods provide delivery of protein-transduction reagent-modified reprogramming proteins to cancer cells, such as tumor cells, as well as diseased cells of diseased tissues and provide in vivo conversion of diseased cells into normal cells via protein-induced in situ cell reprogramming without administration of nucleic acids to the subject..
Wayne State University
Coagulation factor-targeting to tlt-1 on activated platelets
The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament.
Novo Nordisk A/s
Formulations of single domain antigen binding molecules
The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of tnf-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins.
Compositions and methods for promoting the mineralization of biological tissue
This invention relates to compositions and methods for activating and promoting mineralization in tissue that does not normally mineralize, specifically intervertebral discs. The composition comprises agents that increase the expression of the gene that encodes tnap and/or the activation, amount or activity of tnap protein, and agents that decrease the expression of ank and/or enpp and/or the activation, amount or activity of these proteins.
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery
Modified binding proteins inhibiting the vegf-a receptor interaction
The present invention relates to binding proteins specific for vegf-a, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits vegf-axxx binding to vegfr-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety.
Molecular Partners Ag
Active ingredient capsules
Active ingredient capsules are proposed which are obtainable by, with the input of mechanical and thermal energy, (a) dissolving and/or dispersing proteins, polysaccharides and cellulose derivatives in water, (b) adding the active ingredients to be encapsulated, (c) hardening the resulting coacervates with the addition of tannins and optionally (d) then subjecting them to a spray drying.. .
High protein distillers dried grains with solubles and methods thereof
Distillers dried grain with solubles (ddgs), such as ddgs from an ethanol process, can undergo a denaturing process resulting in higher measurable protein content. The denatured ddgs byproduct, which may include higher measurable rumen undegradable protein products or bypass proteins, can be used to produce distillers meal, which may be used as an animal feed and are able to survive the digestive process through the rumen of ruminant animals that results in more protein bioavaible to the ruminant animal in the later stages of digestion and absorption.
Novita Nutrition, Llc
Computational approach for identifying a combination of two drugs
The present invention relates to a method for identifying a therapeutic drug combination against a cancer, wherein the cancer comprises at least two alterations in at least two different, but crosstalking signaling pathways, the method comprising the steps of: a) providing a kinetic model of a biological network for said cancer comprising the at least two different, but crosstalking signaling pathways, wherein the kinetic model is generated by choosing a network topology, wherein the nodes of said topology represent biological entities selected from the group comprising genes, transcripts, peptides, proteins, protein modification states, small molecules, complexes, metabolites and modifications thereof, and the edges of said topology represent interactions between said entities, assigning kinetic laws and kinetic constants to the interactions and assigning concentrations to the biological entities, such that the kinetic model reflects the genome, epi-genome, proteome and/or transcriptome of said cancer, b)selecting test combinations from a plurality of known drugs, each test combination comprising at least two drugs, c) simulating the effect of each test combination on the biological network, thereby d) identifying from said test combinations a drug combination that acts against said cancer.. .
Alacris Theranostics Gmbh
Novel phenyl glyoxal probes
Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described..
Methods for assessing risk for cardiac dysrythmia in a human subject
The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing andersen's syndrome. A tissue sample from a patient is obtained and the dna or proteins of the sample isolated.
University Of Utah Research Foundation
N-glycosylation of peptides and proteins
A process for the production of a glycoconjugate by n-glycosylation of a protein or peptide comprising the sequence d/e-x—n—x—s/t, wherein each x is the same or different and is any natural amino acid other than proline, wherein the process comprises reacting the protein or peptide with a polyisoprenyl pyrophosphate of formula (i), or a salt thereof, in the presence of pglb: (i) to produce the glycoconjugate comprising the protein or peptide having a saccharide [si] linked to the asparagine in the sequence d/e-x—n—x—s/t. Polyisoprenylpyrophosphates used as substrates in the biocatalytic process are also provided, as well as certain glycoconjugates..
Isis Innovation Limited
Interfering with hd-zip transcription factor repression of gene expression to produce plants with enhanced traits
A recombinant dna construct is disclosed. When the recombinant dna construct is expressed in a plant or a plant cell, endogenous hd-zip class ii proteins become less able to repress dna transcription of the genes they typically regulate.
Monsanto Technology Llc
Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression.
Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
An antibody comprising an antigen recognition region which comprises cdr amino acid sequences set forth in seq id no: 7, 8, 9, 10, 11 and 12.. .
Yeda Research And Development Co. Ltd.
Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.. .
Momenta Pharmaceuticals Inc.
Bifunctional stapled polypeptides and uses thereof
The invention relates to bifunctional stapled or stiched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or stiched peptides that bind to an effector biomolecule through the effector domain and bind to a target biomolecule through the targeting domain.
President And Fellows Of Harvard College
Desmoglein 2 (dsg2) binding proteins and uses therefor
The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.. .
University Of Washington Through It's Center For Commercialization
Hiv-1 antigens with discrete conformational forms on the v1/v2 domain and methods of use thereof
The present invention relates to a novel composition of hiv-1 env proteins that contain structurally and immunologically distinct vi/v2 domains. Methods of isolating such proteins, and methods of using such proteins as immunogens, therapeutic agents, vaccines, and test compounds for use in identifying a hiv antiviral are also provided..
Rutgers, The State University Of New Jersey